{{Rsnum
|rsid=17036314
|Gene=PPARG
|Chromosome=3
|position=12335246
|Orientation=plus
|GMAF=0.2681
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=PPARG
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 4.7 | 32.8 | 62.5
| HCB | 2.2 | 40.0 | 57.8
| JPT | 11.1 | 33.3 | 55.6
| YRI | 3.2 | 27.0 | 69.8
| ASW | 0.0 | 0.0 | 0.0
| CHB | 2.2 | 40.0 | 57.8
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}
[[rs17036314]] is a SNP in the peroxisome proliferator-activated receptor gamma [[PPARG]] gene.

In a 4 year study of 479 overweight individuals with impaired glucose tolerance (IGT) who participated in the Finnish Diabetes Prevention Study (DPS), carrying a [[rs17036314]](C) allele predicted conversion to [[type-2 diabetes]] (T2D) after adjustment for baseline fasting glucose (p=0.030). Increased physical activity reduced this risk.{{PMID|18091023}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}